Research & development increased 17.3%
Research & development changed +17.3% from the comparable as-filed period.
$273.8M→$321.3M3 prior comparisons
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed +17.3% from the comparable as-filed period.
SBC / revenue changed -1021 basis points from the comparable as-filed period.
Selling, general & administrative changed +17.0% from the comparable as-filed period.
Stock-based compensation changed -17.2% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.